Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 601–700 of 1,029
NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy
Lim, R. R., Wieser, M. E., Ganga, R., Barathi, V. A., Lakshminarayanan, R., Mohan, R. R., Hainsworth, D. P., & Chaurasia, S. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030899 · Cited by 61
“Regardless of age at DM onset, statistics show that DM patients generally develop DR within ten years of diagnosis [18,23].”
BackgroundTang, L., Zhang, C., Yang, Q., Xie, H., Liu, D., Tian, H., Lu, L., Xu, J., Li, W., Xu, G., et al. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30269 · Cited by 58
“Diabetic retinopathy (DR), a microvascular complication of diabetes mellitus, remains one of the major causes of blindness worldwide (Yau et al., 2012).”
BackgroundCurcumin Metabolite Tetrahydrocurcumin in the Treatment of Eye Diseases
Kao, Y.-W., Hsu, S., Chen, J. Y., Lin, I., Chen, K., Lee, P., Ng, H. S., Chiu, C., & Cheng, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010212 · Cited by 59
“Therefore, apart from diabetes, hypertension, and obesity are most significantly associated with DR [38,39].”
BackgroundSilva, M., Peng, T., Zhao, X., Li, S., Farhan, M., & Zheng, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.007 · Cited by 58
Tavakoli, M., Mehdizadeh, A., Aghayan, A., Pourreza, R., Ellis, T., & Dehmeshki, J. (2021) · IEEE Access · doi:10.1109/access.2021.3074458 · Cited by 58
“More-over, one out of ten tolerates DR severity and vision loss [4].”
BackgroundThe Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 61
Self-citationSzeto, S., Hui, V. W. K., Tang, F. Y., Yang, D., Sun, Z., Mohamed, S., Chan, C. K. M., Lai, T. Y. Y., & Cheung, C. Y.-L. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319587 · Cited by 66
ALKBH5-Mediated m6A Modification of A20 Regulates Microglia Polarization in Diabetic Retinopathy
Chen, T., Zhu, W., Wang, C., Dong, X., Yu, F., Su, Y., Huang, J., Huo, L., & Wan, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813979 · Cited by 74
“Diabetic retinopathy (DR), one of the most common complications of diabetes mellitus, is the leading cause of blindness and visual impairment among working-age adults global (2, 3).”
BackgroundDiabetic retinopathy: A review on its pathophysiology and novel treatment modalities
Morya, A. K., Ramesh, P. V., Nishant, P., Kaur, K., Gurnani, B., Heda, A., & Salodia, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i4.95881 · Cited by 58
Prevalence and Associated Factors of Diabetic Retinopathy in Rural Central India
Jonas, J. B., Nangia, V., Khare, A., Matin, A., Bhojwani, K., Kulkarni, M., Sinha, A., Lambat, S. P., Gupta, R., & Panda‐Jonas, S. (2013) · Diabetes Care · doi:10.2337/dc12-2377 · Cited by 58
Botanical Compounds: Effects on Major Eye Diseases
Huynh, T.-P., Mann, S. N., & Mandal, N. A. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/549174 · Cited by 60
“The laser treatment helps shrink the abnormal blood vessels, but in cases of severe bleeding a vitrectomy is required to remove the blood from the center of the eye [17, 18].”
BackgroundPonto, K. A., Koenig, J., Pető, T., Lamparter, J., Raum, P., Wild, P. S., Lackner, K. J., Pfeiffer, N., & Mirshahi, A. (2016) · Diabetologia · doi:10.1007/s00125-016-4013-5 · Cited by 58
“been shown that 14/35 studies on diabetic retinopathy have not applied pupil dilation [33].”
BackgroundSleep and diabetic retinopathy
Jee, D., Keum, N., Kang, S., & Arroyo, J. G. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13169 · Cited by 61
Quality of Life in People with Diabetic Retinopathy: Indian Study
Pereira, D. M. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/24496.9686 · Cited by 60
“[19] Global prevalence and major risk factors of diabetic retinopathy.”
BackgroundResultGenome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy
Graham, P. S., Kaidonis, G., Abhary, S., Gillies, M. C., Daniell, M. D., Essex, R. W., Chang, J. H., Lake, S. R., Pal, B., Jenkins, A. J., et al. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0587-8 · Cited by 58
Self-citationChen, Y., Wu, A., Chuang, C., & Chen, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47241-1 · Cited by 58
Self-citationCui, Y., Zhang, M., Zhang, L., Zhang, L., Kuang, J., Zhang, G., Liu, Q., Guo, H., & Meng, Q. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023586 · Cited by 65
Intravitreal steroids for macular edema in diabetes
Rittiphairoj, T., Mir, T. A., Li, T., & Virgili, G. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005656.pub3 · Cited by 58
Li, M., Wang, Y., Liu, Z., Tang, X., Mu, P., Tan, Y. C. R. S., Wang, J., Lin, B., Deng, J., Peng, R., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/5814296 · Cited by 64
“This may be attributed to fact that older patients had longer diabetes duration, which was a strong risk factor for the prevalence of DR [2, 3, 10, 15, 23].”
BackgroundSelf-citationArtificial intelligence for diabetic retinopathy
Li, S., Zhao, R., & Zou, H. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001816 · Cited by 65
“[8] In China, 18.45% of the population with diabetes DR, and a longer course of diabetes is associated with a higher prevalence of DR. [9] Respectively, 17.6% [10] and 33.2% [11] of diabetic patients in India and the United States developed DR. DR is progressive and it is associated with the risk…”
BackgroundInfluentialCai, K., Liu, Y., & Wang, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3586 · Cited by 64
“retina resulting from the prolonged exposure to the metabolic changes induced by DM and has been recognized as the leading cause of blindness and visual impairment among working‐age population around the world.(6)”
BackgroundDong, C., Wu, G., Li, H., Qiao, Y., & Gao, S. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14146 · Cited by 61
“Eye and kidney diseases are common complications of diabetes, leading to blindness and renal failure 11,12 .”
BackgroundDisorganized Retinal Lamellar Structures in Nonperfused Areas of Diabetic Retinopathy
Dodo, Y., Murakami, T., Uji, A., Yoshitake, S., & Yoshimura, N. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15924 · Cited by 57
Yun, J., Lim, T., Cha, S., Ahn, Y., Song, K., Choi, J. A., Kwon, J., Jee, D., Cho, Y. K., Park, Y., et al. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.6.482 · Cited by 62
DeBuc, D. C. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0827-2 · Cited by 60
“The original OCT device used a timedomain approach and produced 2-D optical images similar to ultrasound imaging or to in vivo histopathology. Since its introduction, OCT technology has revolutionized the clinical ophthalmic practice [19]. OCT has been used to measure the total thickness of the retina and its volume.…”
BackgroundMethodInfluentialLi, T., Jia, Y., Wang, S., Wang, A., Gao, L., Yang, C., & Zou, H. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25499 · Cited by 57
MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy
Greco, M., CHIEFARI, E. D., Accattato, F., Corigliano, D. M., Arcidiacono, B., Mirabelli, M., Liguori, R., Brunetti, F. S., Pullano, S. A., Scorcia, V., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00528 · Cited by 60
“Among diabetes-related microvascular complications (namely retinopathy, neuropathy and nephropathy), diabetic retinopathy (DR) is one of the most devastating and frequent injuries, affecting over 30% of patients with diabetes, and one of the leading causes of vision loss in the working-age population (4, 5).”
BackgroundLi, B., Chen, H., Zhang, B., Yuan, M., Jin, X., Lei, B., Xu, J., Gu, W., Wong, D., He, X., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316290 · Cited by 68
Retinal Physiology and Circulation: Effect of Diabetes
Wright, W. S., Eshaq, R. S., Lee, M., Kaur, G., & Harris, N. R. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190021 · Cited by 63
Role of plasma kallikrein in diabetes and metabolism
Zhou, Q., Fickweiler, W., & Feener, E. P. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0179 · Cited by 58
Update on wide- and ultra-widefield retinal imaging
Kozak, I., Shoughy, S. S., & Arevalo, J. (2015) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.167122 · Cited by 56
“[12,13] Diabetic macular edema (DME) is a major cause of vision loss among diabetic patients.”
Gasotransmitters in Vascular Complications of Diabetes
van den Born, J. C., Hammes, H., Greffrath, W., van Goor, H., & Hillebrands, J. (2016) · Diabetes · doi:10.2337/db15-1003 · Cited by 58
Retinal image quality assessment based on image clarity and content
Abdel‐Hamid, L., El-Rafei, A., Elramly, S., Michelson, G., & Joachim Hornegger, A. (2016) · Journal of Biomedical Optics · doi:10.1117/1.jbo.21.9.096007 · Cited by 56
Giocanti‐Auregan, A., Hrarat, L., Qu, L., Sarda, V., Boubaya, M., Lévy, V., Chaine, G., & Fajnkuchen, F. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20855 · Cited by 56
Hashemi, H., Yekta, A., Jafarzadehpur, E., Doostdar, A., Ostadimoghaddam, H., & Khabazkhoob, M. (2017) · Eye · doi:10.1038/eye.2017.68 · Cited by 56
Dhoot, D. S., Baker, K. H., Saroj, N., Vitti, R., Berliner, A. J., Metzig, C., Thompson, D. E., & Singh, R. P. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.06.029 · Cited by 56
“The prevalence of DME in the global diabetic population is estimated to be roughly 7%.(2) In diabetic patients, hyperglycemia is the triggering factor for tissue alterations such as damage to capillary endothelial cells in the retina and blood-retinal barrier breakdown.”
Mitchell, P., McAllister, I. L., Larsen, M., Staurenghi, G., Korobelnik, J., Boyer, D. S., Diana, V., Brown, D. M., Katz, T. A., Berliner, A. J., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.02.011 · Cited by 63
Self-citationProgress in Carotenoid Research
Zepka, L. Q., Lopes, E. J., & de Rosso, V. V. (2018) · InTech eBooks · doi:10.5772/intechopen.73775 · Cited by 57
Diabetic Retinopathy Screening Using Smartphone-Based Fundus Imaging in India
Wintergerst, M. W. M., Mishra, D. K. C., Hartmann, L., Shah, P. N., Konana, V. K., Sagar, P., Berger, M., Murali, K., Holz, F. G., Shanmugam, M. P., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.05.025 · Cited by 65
Admin, A., Curovic, V. R., Suvitaival, T., Ismo, M., Ahonen, L., Trôst, K., Theilade, S., Hansen, T. W., Legido‐Quigley, C., & Rossing, P. (2020) · Diabetes · doi:10.2337/db20-0104 · Cited by 60
“6% in a large meta-analysis including 22,896 individuals with diabetes (2).”
Lawrenson, J. G., Bourmpaki, E., Bunce, C., STRATTON, I. M., Gardner, P., Anderson, J., & EROS Study Group (2020) · Diabetic Medicine · doi:10.1111/dme.14425 · Cited by 59
The Metaflammatory and Immunometabolic Role of Macrophages and Microglia in Diabetic Retinopathy
Wu, H.-L., Wang, M., Li, X., & Shao, Y. X. (2021) · Human Cell · doi:10.1007/s13577-021-00580-6 · Cited by 56
New Insights into Treating Early and Advanced Stage Diabetic Retinopathy
Simó, R., & Hernández, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158513 · Cited by 56
Saleh, G. A., Batouty, N. M., Haggag, S., Elnakib, A. A., Khalifa, F., Taher, F., Mohamed, M. A., Farag, R. K., Sandhu, H. S., Sewelam, A., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9080366 · Cited by 67
“DR and DME are considered the leading cause of blindness worldwide, and lead to significant visual morbidity [2,4].”
BackgroundVitreous humor in the pathologic scope: Insights from proteomic approaches
Monteiro, J. P., Santos, F. M., Rocha, A. S., Sousa, J. P. C., Queiroz, J. A., Passarinha, L. A., & Tomaz, C. T. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400133 · Cited by 60
“Diabetic macular edema (DME) is an ocular condition commonly related with diabetes, representing the primary cause of poor visual acuity and visual impairment in patients [96–98].”
BackgroundJee, D., Han, K., & Kim, E. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115199 · Cited by 55
“Major risk factors for DR include a longer diabetes duration, poor glycemic control, and hypertension, which have been strongly and consistently associated with DR across populations [2].”
BackgroundMethodUpdate on genetics and diabetic retinopathy
Schwartz, S. G., Hampton, B. M., Brantley, M. A., & Flynn, H. W. (2015) · Clinical ophthalmology · doi:10.2147/opth.s94508 · Cited by 59
Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy
Ramsey, D. J., & Arden, G. B. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0686-2 · Cited by 59
Lin, S., Ramulu, P., Lamoureux, E. L., & Sabanayagam, C. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12745 · Cited by 54
“6% among people with diabetes globally.(2,4,5) Several landmark studies, including the Early Treatment Diabetic Retinopathy Study (ETDRS), have shown that blindness from DR is almost entirely preventable given early detection, treatment and effective diabetes control.”
BackgroundSelf-citationDiabetic retinopathy screening: global and local perspective
Gangwani, R. A., Lian, J., McGhee, S. M., Wong, D., & Li, K. K. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj164844 · Cited by 55
Schreur, V., van Asten, F., Ng, H., Weeda, J., Groenewoud, J. M. M., Tack, C. J., Hoyng, C. B., de Jong, E. K., Klaver, C. C. W., & Klevering, B. J. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13815 · Cited by 57
Trost, A., Bruckner, D., Rivera, F. J., & Reitsamer, H. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11093-2_1 · Cited by 58
An Ophthalmologist's Guide to Deciphering Studies in Artificial Intelligence
Ting, D. S. W., Lee, A. Y., & Wong, T. Y. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.014 · Cited by 53
Self-citationNeurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
The Role of Vitamin D in the Pathogenesis and Treatment of Diabetes Mellitus: A Narrative Review
Grammatiki, M., Karras, S., & Kotsa, K. (2019) · Hormones · doi:10.1007/s42000-018-0063-z · Cited by 54
“sion, smoking, inflammation, insulin resistance, anemia, dyslipidemia, obesity, and microalbuminuria [115].”
Adaptive optics ophthalmoscopy: a systematic review of vascular biomarkers
Bakker, E., Dikland, F. A., van Bakel, R., Jesus, D. A. D., Brea, L. S., Klein, S., van Walsum, T., Rossant, F., Farias, D. C., Grieve, K. F., et al. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.012 · Cited by 54
Abitbol, E., Mière, A., Excoffier, J.-B., Mehanna, C.-J., Amoroso, F., Kerr, S., Ortala, M., & Souied, E. H. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2021-000924 · Cited by 56
Kim, S.-J., Yoo, W.-S., Choi, M.-Y., Chung, I. Y., Yoo, J.-M., & Choi, W.-S. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1006372 · Cited by 56
“Taken together, our data suggest that hyperglycemia increases O-GlcNAcylation of retinal proteins in DR and that O-GlcNAcylation of the NF-kB p65 subunit is involved in hyperglycemia-induced NF-kB activation and RGC death in DR.”
BackgroundInfluentialTelemedicine in diabetic retinopathy: Current status and future directions
Das, T., Raman, R., Ramasamy, K., & Rani, P. K. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.154391 · Cited by 57
Statistical atlas based exudate segmentation
Ali, S., Sidibé, D., Adal, K. M., Giancardo, L., Chaum, E., Karnowski, T. P., & Mériaudeau, F. (2013) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2013.06.006 · Cited by 54
Role of Angiopoietins and Tie-2 in Diabetic Retinopathy
Khalaf, N. A., Helmy, H., labib, H., Fahmy, I., Hamid, M. A. E., & Moemen, L. A. (2017) · Electronic physician · doi:10.19082/5031 · Cited by 54
Therapeutic targets for altering mitochondrial dysfunction associated with diabetic retinopathy
Kowluru, R. A., & Mishra, M. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439921 · Cited by 55
“5% diabetic patients aged 40 years and older have retinopathy; in 2010, 93 million people had diabetic retinopathy [3], and with the incidence of diabetes increasing”
BackgroundSule, O. O. (2022) · IEEE Access · doi:10.1109/access.2022.3163247 · Cited by 65
“The most common DR risk factors are prolonged or poorly managed diabetes mellitus, high blood pressure, pregnancy, age, and high cholesterol, all of which affect the visual tissue [6].”
BackgroundDietary Intake and Diabetic Retinopathy: A Systematic Review of the Literature
Shah, J., Cheong, Z. Y., Tan, B., Wong, D. W. K., Liu, X., & Chua, J. (2022) · Nutrients · doi:10.3390/nu14235021 · Cited by 60
“Lastly, DME is a vision-threatening manifestation of DR, more commonly seen in severe stages of DR [28], and the association between diet and DME has not been reported in previous reviews.”
BackgroundInfluentialArtificial intelligence for telemedicine diabetic retinopathy screening: a review
Nakayama, L. F., Ribeiro, L. Z., Novaes, F. D. C., Miyawaki, I. A., Miyawaki, A. E., de Oliveira, J. A. E., de Oliveira, T. V. F., Malerbi, F. K., Regatieri, C. V., Celi, L. A., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2258149 · Cited by 57
Schmit-Eilenberger, V. K. (2015) · Clinical ophthalmology · doi:10.2147/opth.s79785 · Cited by 53
“1 ran (5), Bev (7) Tri (2) [10 mg], Dex (2)”
InfluentialDongare, S., Gupta, S. K., Mathur, R., Saxena, R., Mathur, S. R., Agarwal, R., Nag, T. C., Srivastava, S., & Kumar, P. (2016) · PubMed Central · Cited by 53
Uyar, S., Balkarlı, A., Erol, M. K., Yeşil, B., Tokuç, A., Durmaz, D., Görar, S., & Çekın, A. H. (2016) · Journal of Diabetes Research · doi:10.1155/2016/7592402 · Cited by 53
van der Wijk, A., Vogels, I. M. C., Noorden, C. J. F. V., Klaassen, I., & Schlingemann, R. O. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21091 · Cited by 53
A hybrid deep learning model for detecting diabetic retinopathy
Seth, S., & Agarwal, B. (2018) · Journal of Statistics and Management Systems · doi:10.1080/09720510.2018.1466965 · Cited by 53
“It is the biggest source of preventable blindness, accounting for more than 93 million cases worldwide[1].”
BackgroundCorrelations among Diabetic Microvascular Complications: A Systematic Review and Meta-analysis
Li, J., Cao, Y., Liu, W., Wang, Q., Qian, Y., & Lu, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-40049-z · Cited by 53
Spermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy
Narayanan, S. P., Shosha, E., & Palani, C. D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104299 · Cited by 58
“A pooled meta-analysis study of 35 population-based (mostly from developed countries) reported that more than 90 million individuals are estimated to have DR[31].”
BackgroundHan, N., Xu, H., Yu, N., Wu, Y., & Li, Y. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13163 · Cited by 53
Lang, G. E., Stahl, A., Voegeler, J., Quiering, C., Lorenz, K., Spital, G., & Liakopoulos, S. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14312 · Cited by 53
“Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus occurring in one-third of the 285 million diabetic patients worldwide (Yau et al. 2012).”
BackgroundPeng, Q., Tong, P., Gu, L., & Li, W. (2020) · Bioscience Reports · doi:10.1042/bsr20192121 · Cited by 55
Choroidal Thickness in Diabetic Patients Without Diabetic Retinopathy: A Meta-analysis
Endo, H., Kase, S., Saito, M., Yokoi, M., Takahashi, M., Ishida, S., & Kase, M. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.05.036 · Cited by 53
Pawar, S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3939242 · Cited by 54
Zhuang, X., Cao, D., Zeng, Y., Yang, D., Yao, J., Kuang, J., Xie, J., He, M., Cai, D., Zhang, S., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108373 · Cited by 52
CARNet: Cascade attentive RefineNet for multi-lesion segmentation of diabetic retinopathy images
Guo, Y., & Peng, Y. (2022) · Complex & Intelligent Systems · doi:10.1007/s40747-021-00630-4 · Cited by 56
Wang, H., Guo, Z., & Xu, Y. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03425-4 · Cited by 61
“DR as a vascular and neurodegenerative disease occurs after some years of poorly controlled diabetes [4].”
BackgroundAssociations between psycho-behavioral risk factors and diabetic retinopathy: NHANES (2005–2018)
Sun, X., Zhang, G.-H., Guo, C., Zhou, Z., Niu, Y., Wang, L., & Dou, G. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966714 · Cited by 58
Current research and future strategies for the management of vision-threatening diabetic retinopathy
Li, H., Jia, W., Vujosevic, S., Sabanayagam, C., Grauslund, J., Sivaprasad, S., & Wong, T. Y. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100109 · Cited by 59
Self-citationZhong, X., Du, Y., Yuan, L., Liu, N., Guo, Y., & Pan, T. (2015) · Gene · doi:10.1016/j.gene.2015.04.045 · Cited by 52
Treps, L., Conradi, L., Harjes, U., & Carmeliet, P. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012492 · Cited by 57
Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Wang, J.-H., Ling, D. L., Tu, L., van Wijngaarden, P., Dusting, G. J., & Liu, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.01.003 · Cited by 59
“The presence of at least one of these forms of the disease is referred to as vision-threatening DR (Yau et al., 2012).”
Self-citationAcharya, N. K., Qi, X., Goldwaser, E. L., Godsey, G. A., Wu, H., Kosciuk, M. C., Freeman, T. A., Macphee, C. H., Wilensky, R. L., Venkataraman, V., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116683149 · Cited by 54
Cui, J., Gong, R., Hu, S., Cai, L., & Chen, L. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.007 · Cited by 52
“Diabetic retinopathy (DR) is a serious microvascular complication of diabetes, which has been the leading cause of blindness among activeage people in most developed nations [1].”
BackgroundLiang, Z., Gao, K., Wang, Y. X., Liu, Z. C., Tian, L., Yang, X., Ding, J. Y., Wu, W., Yang, W., Li, Y. L., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00021.2018 · Cited by 59
“Diabetic retinopathy (DR) is one of the major complications of diabetes and the leading cause of visual impairment or blindness in patients with either type 1 or type 2 diabetes mellitus (T2DM) (7, 40).”
BackgroundMidena, E., Micera, A., Frizziero, L., Pilotto, E., Esposito, G., & Bini, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-46515-y · Cited by 55
Balkhi, B. S., Alwhaibi, M., Alqahtani, N., Alhawassi, T. M., Alshammari, T. M., Mahmoud, M. A., AlMetwazi, M. S., Ata, S. I., & Kamal, K. M. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029280 · Cited by 55
Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis
Leng, Y., Li, X., Li, C., & Bai, D. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.286974 · Cited by 53
“Yau et al. (2012) 19 Review No specific cell information description To examine the global prevalence and major risk factors for diabetic retinopathy and vision-threatening diabetic retinopathy among people with diabetes Busik et al. (2009) 18 Animal experiment Endothelial progenitor cells This…”
BackgroundDiabetic Retinopathy Screening: A Systematic Review of Qualitative Literature
Egunsola, O., Dowsett, L. E., Diaz, R. L., Brent, M. H., Rac, V. E., & Clement, F. M. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.014 · Cited by 52
Fundus Autofluorescence and Clinical Applications
Pole, C., & Ameri, H. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9439 · Cited by 55
“DR affects approximately 35% of the more than 422 million adults suffering from diabetes worldwide.[98, 99] Currently, the most commonly used screening and diagnostic modalities for DR include color fundus imaging and FA, both standard and ultrawide field.”
BackgroundUpdates in deep learning research in ophthalmology
Ng, W. Y., Zhang, S., Wang, Z., Ong, C., Gunasekeran, D. V., Lim, G. Y. S., Zheng, F., Tan, S. C. Y., Tan, G. S. W., Rim, T. H., et al. (2021) · Clinical Science · doi:10.1042/cs20210207 · Cited by 54
Luo, S., Shi, C., Wang, F., & Wu, Z. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13111142 · Cited by 52
“In addition, the risk effect may depend on the interaction with other risk factors: diabetes duration, HbA1c, blood pressure, total serum cholesterol, control of diabetes, and body mass index, all of which modulate the development of DR [3].”
BackgroundAlHargan, M., AlBaker, K., Alfadhel, A., AlGhamdi, M., AlMuammar, S., & AlDawood, H. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_422_18 · Cited by 51
Hybrid Graph Convolutional Network for Semi-Supervised Retinal Image Classification
Zhang, G., Pan, J. S., Zhang, Z., Zhang, H., Xing, C., Sun, B., & Li, M. (2021) · IEEE Access · doi:10.1109/access.2021.3061690 · Cited by 59
“That makes the DR become one of the most complicated diseases in diabetic patients [48].”
BackgroundMcCullough, P., Mohite, A., Virgili, G., & Lois, N. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.5817 · Cited by 60
Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease
Muniyandi, A., Hartman, G. D., Song, Y., Mijit, M., Kelley, M. R., & Corson, T. W. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001563 · Cited by 54
“PDR affects about 7%, and diabetic macular edema affects 7% (Yau et al., 2012). nAMD, although only accounting for about 10% of the more than 200 million total age-related macular degeneration (AMD) patients worldwide (Wong et al., 2014), is responsible for 90% of AMD-related blindness (Ferris et…”
BackgroundYang, D., Tang, Z., Ran, A. R., Nguyen, T. X., Szeto, S., Chan, J., Wong, C. Y., Hui, V. W. K., Tsang, K. K., Chan, C. K. M., et al. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2023.1821 · Cited by 53
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.